Journal of Clinical Trials
Open Access
ISSN: 2167-0870
ISSN: 2167-0870
Department of Pharmaceutical Sciences, Isra University, Queen Alya Airport Street, Amman 11622, Jordan
Research Article
Atrial fibrillation, Stroke and the Use of Novel Oral Anticoagulants: A Review of Phase III Randomized Clinical Trials
Author(s): Ahmad Saleh Malkawi*, Azhar Malkawi and Nasr Alrabadi
Atrial Fibrillation (AF) significantly increases the risk of stroke, a leading cause of death and disability. Anticoagulation therapy, traditionally with warfarin, effectively reduces stroke risk but is limited by the need for frequent monitoring to maintain therapeutic international normalized ratio (INR). Novel Anticoagulants (NOVACs), including Direct Thrombin Inhibitors (DTIs) and Direct Factor Xa Inhibitors (DFXaIs), have emerged as promising alternatives. This review examines phase III Randomized Clinical Trials (RCTs) assessing NOVACs for stroke prevention in AF patients compared to warfarin. The RE-LY trial evaluated dabigatran, finding that a low dose (110 mg twice daily) had comparable efficacy to warfarin in reducing stroke and systemic embolism but with a lower risk of major hemorrhage. A higher dose (150 mg twice daily) showed superior efficacy in reducing stroke and syst.. View More»
DOI:
10.35248/2167-0870.25.S32.003